ArticleANZ journal of surgery
International Region of Birth and Long-Term Outcomes for Patients Undergoing Colorectal Cancer Resection in an Australian Population.
Article in ANZ journal of surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOverseas birth is associated with a survival advantage in colorectal cancer in Australia. We wished to analyse this survival based on global region of birth, controlling for cancer-specific and other causes of death.
methodsA database of resected colorectal cancers from 2010 to 2016 (n = 1596) was grouped according to patient global region of birth. Chi-squared testing was used to compare factors including patient demographics and AJCC stage. Kaplan-Meier and competing-risk analysis were used to compare 5-year survival outcomes between patients born in different regions, and regression analysis was used to control for age.
results751 (47.1%) patients were born overseas. 385 (24.1%) originated from Europe, 124 (7.8%) from East and SE Asia, 92 (5.8%) from the Middle East, and the remainder from other global regions. Immigrants from East or SE Asia were more likely to present with node-positive disease (p = 0.048) than those born in Australia. Immigrants from East and SE Asia and the Middle East had significantly better all-cause 5-year survival than patients born in Australia (73.4% and 80.4% vs. 60.4%, p < 0.0001). Immigrants from the Middle East retained their cancer-specific survival advantage after competing risk analysis (HR 0.76, p = 0.027). Immigrants from Europe displayed no significant difference in all-cause or disease-specific survival compared to individuals born in Australia.
conclusionPatients born in the Middle East appear to have a colorectal cancer-specific survival advantage compared to those born in Australia, unrelated to stage at presentation. This has significant implications for prognosis and future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.